Oxabact: truly a new treatment option in patients with (primary) hyperoxaluria?

Bibliography

• Habbig S, Beck BB, Hoppe B. Nephrocalcinosis and urolithiasis in children. Kidney Int 2011;80:1278-91
   PubMed Web of Science ®Google Scholar
• Hoppe B, Beck BB, Milliner DS. The primary hyperoxalurias. Kidney Int 2009;75:1264-71
   PubMed Web of Science ®Google Scholar
• Hueppelshaeuser R, von Unruh GE, Habbig S, Enteric hyperoxaluria, recurrent urolithiasis, and systemic oxalosis in patients with Crohn's disease. Pediatr Nephrol 2012;27(7):1103-9
   Google Scholar
• Beck B, Hoyer-Kuhn HK, Habbig S, Hyperoxaluria and systemic oxalosis: an update on current therapy and future directions. Expert Opin Investig Drugs 2012; [Epub ahead of print]
   Google Scholar
• Sikora P, von Unruh GE, Beck B, Hoppe B. [(13)C(2)]oxalate absorption in children with idiopathic calcium oxalate urolithiasis or primary hyperoxaluria. Kidney Int 2008;73(10):1181-6
   PubMed Web of Science ®Google Scholar
• Allison MJ, Dawson KA, Mayberry WR, Oxalobacter formigenes gen. nov. sp. nov.: oxalate-degrading anaerobes that inhabit the gastrointestinal tract. Arch Microbiol 1985;141:1-7
   PubMed Web of Science ®Google Scholar
• Hatch M, Cornelius J, Allison M, Oxalobacter sp. reduces urinary oxalate excretion promoting enteric oxalate excretion. Kidney Int 2006;69:1-8
   Google Scholar
• Hatch M, Freel RW, Vaziri ND. Regulatory aspects of oxalate secretion in enteric oxalate elimination. J Am Soc Nephrol 1999;10:S324-8
   PubMed Web of Science ®Google Scholar
• Hatch M, Freel RW. Intestinal transport of an obdurate anion: oxalate. Urol Res 2005;33:1-16
   PubMed Web of Science ®Google Scholar
• Hoppe B, Beck B, Gatter N, Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type I (PH I). Kidney Int 2006;70:1305-11
   PubMed Web of Science ®Google Scholar
• Hoppe B, Dittlich K, Fehrenbach H, Reduction of plasma oxalate levels by oral application of Oxalobacter formigenes in 2 patients with infantile oxalosis. Am J Kidney Dis 2011;58:453-5
   PubMed Web of Science ®Google Scholar
• Hoppe B, Groothoff JW, Hulton SA, Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria. Nephrol Dial Transplant 2011;26:3609-15
   PubMed Web of Science ®Google Scholar
• Abe K, Ruan ZS, Maloney PC. Cloning, sequencing and expression of OxIT, the oxalate:formiate exchange protein of Oxalobacter formigenes. J Biol Chem 1996;271:6789-93
   Google Scholar
• Lung HY, Baetz AL, Peck AB. Molecular cloning, DNA sequence and gene expression of the oxalyl-CoA decarboxylase gene, oxc, from the bacterium Oxalobacter formigenes. J. Bacteriol 1994;176:2468-72
   Google Scholar
• Sidhu H, Ogden SD, Lung HY, DNA sequencing and expression of formyl-CoA transferase gene, frc, from Oxalobacter formigenes. J Bacteriol 1997;179:3378-81
   Google Scholar
• Sidhu H, Yenatska L, Ogden SD, Natural colonization of children in the Ukraine with the intestinal bacterium, Oxalobacter formigenes, using a PCR-based detection system. Mol Diagn 1997;2:89-97
   Google Scholar
• van Woerden C , editor. Chapter 07: Quantification of endogenous oxalate production in patients with primary hyperoxaluria type I: a stable isotope method. Primary hyperoxaluria type I: clinical, genetic and biochemical studies. PhD thesis; Amsterdam: 2008. p. 93-102
   Google Scholar
• Grujic D, Salido EC, Shenoy BC, Hyperoxaluria is reduced and nephrocalcinosis prevented with an oxalate-degrading enzyme in mice with hyperoxaluria. Am J Nephrol 2009;29:86-93
   PubMed Web of Science ®Google Scholar
• Hatch M, Gjymishka A, Salido EC, Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of primary hyperoxaluria following intestinal colonization with Oxalobacter. Am J Physiol Gastrointest Liver Physiol 2011;300:G461-9
   PubMed Web of Science ®Google Scholar
• Sidhu H, Schmidt ME, Cornelius JG, Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract dwelling bacterium Oxalobacter formigenes: possible prevention by gut recolonization or enzyme replacement therapy. J Am Soc Nephrol 1999;10(Suppl 14):S334
   Google Scholar
• Kumar R, Mukherjee M, Bhandari M, Role of Oxalobacter formigenes in calcium oxalate stone disease: a study from North India. Eur Urol 2002;41:318-22
   PubMed Web of Science ®Google Scholar
• Kwak C, Jeong JH, Lee Molecular identification of Oxalobacter formigenes with the polymerase chain reaction in fresh or frozen fecal samples. BJU 2001;88:627-32
   PubMed Web of Science ®Google Scholar
• Kwak C, Jeong BC, Kim HK, Molecular epidemiology of fecal Oxalobacter formigenes in healthy adults living in Seoul, Korea. J Endourol 2003;88:627-32
   Google Scholar
• Kaufman DW, Kelly JP, Curhan GC, Oxalobacter formigenes may reduce the risk of calcium oxalate kidney stones. J Am Soc Nephrol 2008;19(6):1197-203
   PubMed Web of Science ®Google Scholar
• Kelly JP, Curhan GC, Cave DR, Factors related to colonization with Oxalobacter formigenes in U.S. adults. J Endourol 2011;25(4):673-9
   PubMed Web of Science ®Google Scholar
• Kleinschmidt K, Mahlmann A, Hautmann R. Anaerobic oxalate-degrading bacteria in the gut decrease fecal and urinary oxalate concentrations in stone formers. In: Ryall R, Bais R, Marshall VR, editors. Urolithiasis 2. Plenum Press, New York, USA; 1993. p. 439-41
   Google Scholar
• Sidhu H, Hoppe B, Hesse A, Absence of Oxalobacter formigenes in cystic fibrosis patients: a risk factor for hyperoxaluria. Lancet 1998;352:1026-8
   PubMed Web of Science ®Google Scholar
• Kumar R, Ghoshal UC, Mittal RD. Infrequency of colonization with Oxalobacter formigenes in inflammatory bowel disease: possible role in renal stone formation. J Gastrol Hepatol 2004;19:1403-9
   PubMed Web of Science ®Google Scholar
• Troxel SA, Sidhu H, Kaul P, Low RK. Intestinal Oxalobacter formigenes colonization and urinary oxalate levels in calcium oxalate stone formers. J Endourol 2003;17(3):173-6
   PubMed Web of Science ®Google Scholar
• Sidhu H, Allison MJ, Chow JM, Rapid reversal of hyperoxaluria in a rat model following probiotic administration of Oxalobacter formigenes. J Urol 2001;166:1487-91
   PubMed Web of Science ®Google Scholar
• Hatch M, Freel RW, Vaziri ND. Regulatory aspects of oxalate secretion in enteric oxalate elimination. J Am Soc Nephrol 1999;10(Suppl14):S324-8
   Google Scholar
• OxThera Report Number: DR-017, 28 Day Oral Gavage Safety and Toxicology Study, 24 January 2007
   Google Scholar
• OxThera Report Number DR-049, OC3: a 6-month oral toxicity study in rats using capsules, 16 May 2008
   Google Scholar
• Tannock GW, Munro K, Harmsen M, Analysis of the fecal microflora of human subjects consuming a probiotic product containing Lactobacillus rhamnosis DR20. Appl Environ Microbiol 2000;66:2578-88
   PubMed Web of Science ®Google Scholar
• Dunne C, Murphy L, Flynn S, Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. Antonie van Leeuwenhoek 1999;76(1-4):279-92
   PubMed Web of Science ®Google Scholar